CytomX Therapeutics (CTMX) Set to Announce Earnings on Wednesday

CytomX Therapeutics (NASDAQ:CTMX) is set to release its earnings data after the market closes on Wednesday, August 7th. Analysts expect CytomX Therapeutics to post earnings of ($0.55) per share for the quarter.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.22. CytomX Therapeutics had a negative net margin of 111.27% and a negative return on equity of 73.62%. The company had revenue of $29.49 million during the quarter, compared to the consensus estimate of $13.59 million. On average, analysts expect CytomX Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

CTMX stock traded up $0.24 during trading on Wednesday, reaching $10.77. The company had a trading volume of 1,328 shares, compared to its average volume of 302,766. CytomX Therapeutics has a 52 week low of $8.94 and a 52 week high of $27.04. The stock has a market cap of $461.27 million, a P/E ratio of -5.17 and a beta of 0.64. The business’s 50 day moving average price is $11.00. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.21 and a current ratio of 4.21.

A number of equities analysts have weighed in on CTMX shares. BidaskClub raised shares of Xilinx from a “hold” rating to a “buy” rating in a research note on Wednesday, July 24th. HC Wainwright reaffirmed a “buy” rating and set a $1.75 target price on shares of Orion Energy Systems in a research note on Wednesday, April 3rd. Nomura decreased their target price on shares of CytomX Therapeutics to $22.00 in a research note on Monday, May 13th. ValuEngine downgraded shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Finally, Mizuho raised their target price on shares of Mcdonald’s from $215.00 to $230.00 and gave the company a “buy” rating in a research note on Monday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $20.22.

About CytomX Therapeutics

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Read More: What is a growth and income fund?

Earnings History for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.